ACHE and schizophrenia: This information combined with the aforementioned cholinergic deficits observed in schizophrenia has provided the basis for the idea of evaluating compounds such as acetylcholinesterase inhibitors (AChEIs), mAChR agonists, nAChR agonists, or allosteric activators of mAChR and nAChRs as therapeutic agents in schizophrenia [reviewed, 33, 19].